Santhosh Sadashiv, MD
Hematology · Pittsburgh, PANPI 1982790200
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,335 of the $14,999 with a category attached, or 88.9%. It is spread thinly across 19 manufacturers, the largest accounting for just 20.9%. Reporting peaked in 2024 at $4,548 and has fallen 93.9% since, to $278 in 2025.
Across 40 payments — averaging $374.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kaneka Medical America LLC$3K
- Johnson & Johnson$3K
- GSK$3K
- Novartis$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Janssen Scientific Affairs, LLC$553
- plus $1K from 13 others
Across 129 payments — averaging $3808.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$328K
- Bristol Myers Squibb$87K
- E.r. Squibb & Sons, L.L.C.$26K
- Amgen$20K
- Takeda Pharmaceuticals U.S.A., Inc.$17K
- GSK$14K
What the payments were for
- Consulting fees$13,33589%
- Speaking & faculty fees$2252%
- Food & beverage$1,0127%
- Education$4273%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kaneka Medical America LLC | 1 | $3,135 |
| Johnson & Johnson | 3 | $2,617 |
| GSK | 2 | $2,600 |
| Novartis | 2 | $2,588 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $2,202 |
| Janssen Scientific Affairs, LLC | 3 | $553 |
| Pfizer | 7 | $311 |
| Menarini Silicon Biosystems, Inc. | 1 | $142 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $137 |
| E.r. Squibb & Sons, L.L.C. | 3 | $126 |
| Amgen | 2 | $116 |
| Gilead | 2 | $112 |
| Astellas Pharma US Inc | 1 | $95 |
| Iovance Biotherapeutics, Inc. | 1 | $70 |
| Jazz Pharmaceuticals Inc. | 1 | $63 |
| Incyte Corporation | 2 | $52 |
| Adaptive Biotechnologies Corporation | 1 | $50 |
| Beigene USA, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIPOSORBER$3,135
- Fabhalta$2,588
- NINLARO$1,925
- BLENREP$1,300
- TECVAYLI$1,260
- TALVEY$300
- DARZALEX$253
- ELREXFIO$150
- CELLSEARCH$142
How this compares
$14,999 in reported general payments places this provider in the 70th percentile of 64 hematology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 160 | $2,349,744 |
| RevlimidLenalidomide | 67 | $1,259,127 |
| PomalystPomalidomide | 21 | $483,089 |
| NinlaroIxazomib Citrate | 28 | $353,443 |
| TasignaNilotinib Hcl | 16 | $280,325 |
| VenclextaVenetoclax | 23 | $220,444 |
| RezurockBelumosudil Mesylate | 12 | $216,643 |
| SprycelDasatinib | 13 | $210,579 |
| Imatinib Mesylate | 12 | $16,459 |
| EliquisApixaban | 18 | $10,681 |
| Cyclosporine ModifiedCyclosporine, Modified | 12 | $5,441 |
| Acyclovir | 268 | $3,783 |
| Dexamethasone | 130 | $1,702 |
| Potassium Chloride | 34 | $438 |
| Oxycodone Hcl | 30 | $370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $126 | $693,66934 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $2,202 | $353,44328 claims |
| NovartisTasigna | $2,588 | $280,32516 claims |
| PfizerEliquis | $311 | $10,68118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 64 hematology providers in Pennsylvania.
Other hematology in Pittsburgh
- Craig SeamanPittsburgh$88K
- Robert KaplanPittsburgh$46K
- Julia XuPittsburgh$33K
- Laura de CastroPittsburgh$16K
- Robert RednerPittsburgh$4K
- Neal SpadaPittsburgh$698
- Erika MoorePittsburgh$110
- Olubusola OluwolePittsburgh$41
- Radhakrishnan RamchandrenWest Reading$233K
- Selina LugerPhiladelphia$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.